Search results for "RATS"

showing 10 items of 3537 documents

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Piroxicam

2014

ABSTRACT Literature and experimental data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release (IR) solid oral dosage forms containing piroxicam in the free acid form are reviewed. Piroxicam solubility and permeability, its therapeutic use and therapeutic index, pharmacokinetic properties, data related to the possibility of excipient interactions and reported BE/bioavailability (BA), and corresponding dissolution data are taken into consideration. The available data suggest that according to the current biopharmaceutics classification system (BCS) and all current guidances, piroxicam would be assigned to BCS Class II. The ex…

DrugChemistry Pharmaceuticalmedia_common.quotation_subjectBiological AvailabilityPharmaceutical ScienceExcipientBioequivalencePharmacologyPiroxicamDosage formBiopharmaceuticsArthritis RheumatoidExcipientsFood-Drug InteractionsPiroxicamPharmacokineticsmedicineAnimalsHumansTissue Distributionmedia_commonChemistryAnti-Inflammatory Agents Non-SteroidalStereoisomerismBiopharmaceutics Classification SystemRatsBioavailabilityIntestinal AbsorptionSolubilityTherapeutic EquivalencyCaco-2 CellsHalf-Lifemedicine.drugJournal of Pharmaceutical Sciences
researchProduct

In-situ forming gel-like depot of a polyaspartamide-polylactide copolymer for once a week administration of Sulpiride

2015

Abstract Objectives An in-situ forming gel-like depot, prepared by using an appropriate polyaspartamide-polylactide graft copolymer, has been employed to release in a sustained way sulpiride. Methods α,β-poly(N-2-hydroxyethyl)-D,L-aspartamide-g-polylactic acid (PHEA-g-PLA) has been used as a polymer component. Its physicochemical properties make possible to dissolve it in N-methyl-2-pyrrolidone, with the obtainment of a solution able to form a gel-like depot once injected into a physiological medium. Cell compatibility of PHEA-g-PLA depot has been investigated, using murine dermal fibroblasts as cell model. 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazo…

DrugDepotPolymersmedia_common.quotation_subjectChemistry PharmaceuticalPolyesterssulpiridePharmaceutical SciencePharmacologyCell Linechemistry.chemical_compoundDrug Delivery SystemsPharmacokineticsPolylactic acidmedicineFluorescence microscopeCopolymerAnimalsViability assayRats Wistarpolylactic acidgraft copolymermedia_commonPharmacologyin-situ forming depotRatsDrug LiberationchemistryRabbitsSulpiridePeptidesαβ-poly(N-2-hydroxyethyl)-DL-aspartamidemedicine.drug
researchProduct

Effect of thickener on disintegration, dissolution and permeability of common drug products for elderly patients

2019

Dysphagia is a very common problem suffered by elderly patients. The use of thickeners during administration in these patients helps to prevent difficulties with swallowing larger solid dosage forms. However, there are several indications when the thickeners may influence disintegration and dissolution processes of solid dosage forms, potentially affecting therapeutic efficacy. In this paper the effects of a commonly used thickener on tablet disintegration, dissolution and subsequent absorption of 6 formulated drugs frequently used in elderly patients (Aspirin, Atenolol, Acenocumarol, Candesartan, Ramipril and Valsartan) in two different administration conditions (intact tablet and crushed …

DrugDrug Compoundingmedia_common.quotation_subjectPharmaceutical Science02 engineering and technologyPharmacology030226 pharmacology & pharmacyPermeabilityDosage form03 medical and health sciences0302 clinical medicinemedicineAnimalsHumansIn patientDissolution testingRats WistarDissolutionAgedmedia_commonViscosityChemistryGeneral Medicine021001 nanoscience & nanotechnologyAtenololRatsDrug LiberationSolubilityPermeability (electromagnetism)Deglutition Disorders0210 nano-technologyTabletsBiotechnologymedicine.drugEuropean Journal of Pharmaceutics and Biopharmaceutics
researchProduct

Preclinical evidence of new opioid modulators for the treatment of addiction.

2010

Addiction to opiates is one of the most severe forms of substance dependence, and despite a variety of pharmacological approaches to treat it, relapse is observed in a high percentage of subjects. New pharmacological compounds are necessary to improve the outcome of treatments and reduce adverse side effects. Moreover, drugs that act on the opioid system can also be of benefit in the treatment of alcohol or cocaine addiction. AREA COVERED BY THIS REVIEW: Recent preclinical studies of pharmacological agents for the treatment of opiate addiction (2008 to the present date).The reader will be informed of the latest drugs shown in animal models to modify dependence on opiates and the reinforcing…

DrugGABA Agentsmedia_common.quotation_subjectNarcotic AntagonistsDrug Evaluation PreclinicalReceptors Opioid muPharmacologyReceptors NicotinicBioinformaticsPharmacotherapyDopamineReceptors Opioid deltaCannabinoid Receptor ModulatorsmedicineAdrenergic alpha-2 Receptor AgonistsAnimalsPharmacology (medical)Adverse effectmedia_commonPharmacologySubstance dependencebusiness.industryAddictionReceptors Opioid kappaAntagonistGeneral Medicinemedicine.diseaseOpioid-Related DisordersRatsSubstance Withdrawal SyndromeOpioidReceptors OpioidDopamine AntagonistsFemalebusinessExcitatory Amino Acid Antagonistsmedicine.drugExpert opinion on investigational drugs
researchProduct

Covalent binding of drug metabolites to DNA ? a tool of predictive value?

1980

The presently available data suggest at least some correlation between covalent binding of drug metabolites to DNA and carcinogenicity of that drug. More data, however, are needed to establish the predictability of covalent DNA binding assays for extrahepatic cancer. A covalent binding assay requires administration of radioactively labelled compound to the experimental animals; the availability of labelled compound and requirements as to radiochemical purity, chemical and biochemical stability are limiting the applicability of this procedure. Many technical pitfalls accompany covalent DNA binding assays. It is concluded that at the present time DNA binding assays do not represent routine pr…

DrugHealth Toxicology and Mutagenesismedia_common.quotation_subjectLiver NeoplasmsDrug Evaluation PreclinicalCovalent bindingDNAGeneral MedicineIn Vitro TechniquesToxicologyPredictive valueMolecular biologyRatschemistry.chemical_compoundLiverchemistryBiochemistryCovalent bondCarcinogensAnimalsStandard testDNACarcinogenDrug metabolismmedia_commonArchives of Toxicology
researchProduct

PLGA nanoparticles are effective to control the colonic release and absorption on ibuprofen.

2018

The oral controlled release (CR) formulations have become more important in recent years. Among them, the polymeric nanoparticles have been thoroughly studied during the last decades, consequently they are extensively employed for a broad range of applications and drugs. The objective of this research was to develop polymeric nanoparticles (NPs) of ibuprofen with poly(lactic-co-glycolic) acid (PLGA) as polymer, and to test their applicability for oral CR formulations development. Different proportions of drug/polymer were employed to develop the ibuprofen NPs and their in vitro release profiles were analysed. The in situ segmental permeability of ibuprofen was tested in Wistar rat and demon…

DrugMaleColonPolymersmedia_common.quotation_subjectPharmaceutical ScienceIbuprofen02 engineering and technologyAbsorption (skin)030226 pharmacology & pharmacyPermeability03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDrug Delivery SystemsPolylactic Acid-Polyglycolic Acid CopolymerIn vivomedicineAnimalsLactic AcidRats Wistarmedia_commonchemistry.chemical_classificationDrug CarriersChromatographyorganic chemicalstechnology industry and agriculturePolymer021001 nanoscience & nanotechnologyIbuprofenControlled releaseRatsPLGAchemistryIntestinal AbsorptionPermeability (electromagnetism)Delayed-Action PreparationsNanoparticles0210 nano-technologyPolyglycolic Acidmedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Development of an ion-pair to improve the colon permeability of a low permeability drug: Atenolol.

2016

Abstract To ensure the optimal performance of oral controlled release formulations, drug colon permeability is one of the critical parameters. Consequently developing this kind of formulations for low permeability molecules requires strategies to increase their ability to cross the colonic membrane. The objective of this work is to show if an ion-pair formation can improve the colon permeability of atenolol as a low permeability drug model. Two counter ions have been tested: brilliant blue and bromophenol blue. The Distribution coefficients at pH 7.00 (DpH7) of atenolol, atenolol + brilliant blue and atenolol + bromophenol blue were experimentally determined in n-octanol. Moreover, the colo…

DrugMaleColonmedia_common.quotation_subjectPharmaceutical ScienceBromophenol blue02 engineering and technology030226 pharmacology & pharmacyPermeability03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineLow permeabilityAnimalsRats WistarColoring Agentsmedia_commonchemistry.chemical_classificationChromatographyBenzenesulfonates021001 nanoscience & nanotechnologyAtenololPermeability (earth sciences)MembranechemistryAtenololParacellular transportDelayed-Action PreparationsBromphenol BlueCounterion0210 nano-technologymedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Comparing metoclopramide electrotransport kinetics in vitro and in vivo.

2010

The purpose of this work was to investigate the transdermal iontophoretic delivery of metoclopramide and to determine (i) the dependence of electrotransport on current density and drug concentration, (ii) the relative contributions of electromigration and electroosmosis and (iii) the feasibility of administering therapeutic amounts of drug, using a drug-sparing iontophoretic configuration. Iontophoretic delivery of metoclopramide (MCL) across dermatomed porcine ear skin was investigated in vitro as a function of concentration (10, 20, 40, 80 and 100mM) and current density (0.1, 0.2 and 0.3mAcm(-2)) using vertical flow-through diffusion cells. In vivo studies were performed in Wistar rats (4…

DrugMaleMetoclopramideMetoclopramideSwinemedia_common.quotation_subjectPharmaceutical SciencePharmacologyPharmaceutical formulationIn Vitro TechniquesPharmacokineticsIn vivomedicineAnimalsRats WistarAntiemetics/pharmacokineticsMetoclopramide/pharmacokineticsmedia_commonTransdermalddc:615IontophoresisChemistryIn vitroRatsAntiemeticsmedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Distribution of clozapine and desmethylclozapine between blood and brain in rats.

1999

Desmethylclozapine is the major metabolite of clozapine in serum. Although the metabolite is pharmacologically active in vitro, the occurrence of desmethylclozapine in brain under steady-state conditions and its role for clinical actions of clozapine are unclear. In this study 20 male Sprague-Dawley rats received five oral doses of clozapine 20 mg/kg at 1.5-h intervals. At 0.5, 1, 2 and 5 h after the last administration, at a time four animals were killed for analysis of clozapine and desmethylclozapine concentrations in serum and brain. The treatment yielded steady-state serum concentrations of clozapine that are considered as therapeutically effective in man. Desmethylclozapine concentrat…

DrugMalemedia_common.quotation_subjectMetaboliteDesmethylclozapinePharmacologyRats sprague dawleyRats Sprague-Dawleychemistry.chemical_compoundMedicineDistribution (pharmacology)AnimalsPharmacology (medical)ClozapineBiological PsychiatryClozapineBiotransformationChromatography High Pressure Liquidmedia_commonPharmacologybusiness.industryBrainDrug applicationSerum concentrationRatsPsychiatry and Mental healthNeurologychemistryNeurology (clinical)businessmedicine.drugAntipsychotic AgentsEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
researchProduct

Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug.

2007

An increasing number of newly developed drugs show bioavailability problems due to poor water solubility. Formulating the drugs as nanosuspensions may help to overcome these problems by increasing saturation solubility and dissolution velocity. In the present study the bioavailability of the poorly soluble fenofibrate following oral administration was investigated in rats. Four formulations were tested: a nanosuspension type DissoCube(R), one solid lipid nanoparticle (SLN) preparation and two suspensions of micronized fenofibrate as reference formulations, one suspension in sirupus simplex and a second in a solution of hydroxyethy-cellulose in physiological saline. Both colloidal drug deliv…

DrugMalemedia_common.quotation_subjectPharmaceutical ScienceAdministration OralBiological AvailabilityPharmacologyModels BiologicalDosage formPharmacokineticsFenofibrateSuspensionsSolid lipid nanoparticlemedicineAnimalsComputer SimulationTissue DistributionSolubilityRats Wistarmedia_commonHypolipidemic AgentsFenofibrateChemistryLipidsBioavailabilityRatsSolubilityDrug deliveryNanoparticlesmedicine.drugAdvanced drug delivery reviews
researchProduct